Clinical Trial: Sublingual Dexmedetomidine for Treating Opioid Withdrawal
Study Status: Completed
Recruit Status: RECRUITING
Condition: Opioid Use Disorder
Study Type: INTERVENTIONAL
Official Title: Phase 1B Study of Sublingual Dexmedetomidine, an Alpha 2 Adrenergic Agonist, for Treating Opioid Withdrawal
Brief Summary:
A major challenge to seeking treatment for opioid use disorder (OUD) is the withdrawal symptoms associated with cessation of opioid use.The signs and symptoms of opioid withdrawal include irritability, anxiety, muscular and abdominal pains, chills, nausea, diarrhea, yawning, runny eyes and nose, sweating, sneezing, weakness, and insomnia.The current gold standard of treatment involves a gradual reduction of the opioid drug dosage (tapering).However, as all opioids have potential for abuse and require careful…
Read more